v3.25.1
Stock-Based Compensation - Non-options (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Jul. 31, 2024
Mar. 31, 2025
Dec. 31, 2024
Mar. 31, 2024
BTI RSU        
Number of shares        
Outstanding, beginning balance (in shares)   27,000    
Granted (in shares)   3,000    
Vested (in shares)   (9,000)    
Cancelled (in shares)   (1,000)    
Outstanding, ending balance (in shares)   20,000 27,000  
Weighted average price        
Unrecognized stock-based compensation expense   $ 537   $ 1,308
BTI RSU | RSU vesting 100% at one year anniversary        
Number of shares        
Granted (in shares)   3,000    
Weighted average price        
Granted, Weighted average price (in dollars per share)   $ 6.14    
Vesting period   1 year    
BTI RSU | RSU vesting 25% at one year and remaining in 12 quarters        
Weighted average price        
Vesting period   4 years    
Vesting (as a percent)   25.00%    
BTI PSU        
Number of shares        
Outstanding, beginning balance (in shares)   70,000    
Granted (in shares) 87,000      
Vested (in shares)   0    
Cancelled (in shares)   (10,000)    
Outstanding, ending balance (in shares)   60,000 70,000  
Weighted average price        
Granted, Weighted average price (in dollars per share) $ 19.2      
Vesting period 1 year      
Unrecognized stock-based compensation expense   $ 0    
OnkosXcel PSU        
Number of shares        
Outstanding, beginning balance (in shares)   1,166    
Granted (in shares)   15    
Cancelled (in shares)   (84)    
Outstanding, ending balance (in shares)   1,082 1,166  
Vested aggregate (in shares)   976    
Weighted average price        
Outstanding, Weighted average price beginning balance (in dollars per share)   $ 5,686    
Cancelled, Weighted average price (in dollars per share)   6,006    
Vested, Weighted average price (in dollars per share)   $ 5,533    
Outstanding, Weighted average price ending balance (in dollars per share)     $ 5,686  
Vesting period   48 months    
Unrecognized stock-based compensation expense   $ 319   782
OnkosXcel RSUs        
Number of shares        
Outstanding, beginning balance (in shares)   176    
Granted (in shares)     140  
Vested (in shares)   (2)    
Cancelled (in shares)   (34)    
Outstanding, ending balance (in shares)   140 176  
Weighted average price        
Unrecognized stock-based compensation expense   $ 50   $ 420